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Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Method: In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to
disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive: tofacitinib 5 mg BID or
tofacitinib 10 mg BID for the duration of the study, or placebo for 3 months followed by tofacitinib 5 mg BID or
tofacitinib 10 mg BID. Patient-reported outcomes (PROs) included: Patient Global Assessment of Disease Activity
(PtGA); Patient Assessment of Pain (Pain); Health Assessment Questionnaire-Disability Index (HAQ-DI); Medical
Outcomes Survey (MOS) Short Form-36 (SF-36); Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F);
and MOS Sleep Scale. Time-to-event data (PtGA and Pain) were collected using an interactive voice response
system daily diary (baseline through day 14).
Results: At month 3, tofacitinib 5 and 10 mg BID demonstrated statistically significant improvements versus placebo in
PtGA (both p < 0.0001), Pain (both p < 0.0001), HAQ-DI (both p < 0.0001), SF-36 Physical (p < 0.0001) and Mental (p < 0.05
[5 mg BID] and p < 0.0001 [10 mg BID]), Component Summary scores and all domain scores (p < 0.05–p < 0.0001) and
FACIT-F (both p < 0.0001). Statistically significant changes from baseline in MOS Sleep Scale were reported for 10 mg BID
(p < 0.05). Benefits of tofacitinib treatment were rapid in onset and significant improvements were reported at week 2 for
PtGA, Pain and HAQ-DI, and differentiation from baseline was seen as early as 3 days after treatment initiation for
interactive voice response system (IVRS) PtGA and IVRS Pain. The numbers needed to treat for patients to report
changes greater than or equal to the minimum clinically important difference in PtGA, Pain, HAQ-DI, SF-36
Physical Component Summary score and FACIT-F ranged between 4.0–6.1 (5 mg BID) and 3.2–5.0 (10 mg BID).
Conclusion: Tofacitinib monotherapy in DMARD-IR patients resulted in statistically significant and clinically meaningful
improvements in multiple PROs versus placebo at month 3, with sustained improvements over 6 months.
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Rheumatoid arthritis (RA) is a chronic autoimmune
disease, which is characterized by systemic inflamma-
tion, persistent synovitis and joint destruction. RA
represents a significant health and socioeconomic
burden, and affects all domains of health-related qual-
ity of life (HRQoL), in particular physical functioning,
pain, fatigue and physical and emotional roles [1, 2],
which patients report are more important to them
than joint counts and laboratory tests [3]. Both the
US Food and Drug Administration and European
Medicines Agency emphasize that patient-reported
outcomes (PROs) selected for evaluation in a random-
ized controlled trial (RCT) should be targeted to the
specific patient population [4, 5]. The Outcomes Mea-
sures in Rheumatology (OMERACT) international
consensus effort recommends use of disease-specific
and generic instruments to assess physical function,
HRQoL and fatigue in RCTs in RA [3, 6–8].
The goal of therapy should be to use a treat-to-target
strategy to achieve remission, if possible, or low disease
activity, while limiting joint destruction, maintaining
physical function and optimizing HRQoL [9]. Standard-
of-care treatment includes conventional nonbiologic
and/or biologic disease-modifying antirheumatic drugs
(cDMARDs and bDMARDs, respectively) [10]. Patients
who do not achieve remission, or low disease activity
with advanced disease, with methotrexate and/or other
cDMARDs are often escalated to treatment with
bDMARDs (often in combination with cDMARDs),
including cytokine inhibitors (tumor necrosis factor
inhibitors, interleukin (IL)-6 inhibitors, IL-1 inhibitors),
B cell inhibitors and B-T cell co-stimulation modulators
[9, 11, 12]. As not all patients respond adequately to
these medications, an unmet need for additional therap-
ies persists, including those with alternative mechanisms
of action.
Tofacitinib is an oral Janus kinase (JAK) inhibitor
which preferentially inhibits signaling by heterodi-
meric receptors associated with JAK3 and/or JAK1,
with functional selectivity over those that signal via
pairs of JAK2 [13].
Administration of tofacitinib 5 and 10 mg orally twice
daily (BID) has demonstrated sustained efficacy with a
manageable safety profile in patients with RA in phase 2
[14–18] and phase 3 [19–24] RCTs of up to 24 months’
duration, and in long-term extension studies for up to
7 years [25, 26].
The phase 3 ORAL Solo RCT (A3921045) was de-
signed to assess the efficacy and safety of tofacitinib
monotherapy in patients with active RA, who had prior
inadequate responses to cDMARDs or bDMARDs. The
primary efficacy (including HAQ-DI) and safety data
have been reported elsewhere [21], and showed thattofacitinib monotherapy results in reductions in signs
and symptoms of active RA including improvement in
physical function, with a manageable safety profile over
6 months. Here we present the complete profile of PROs
from this phase 3 trial.
Methods
Study design and treatment
This was a phase 3, 6-month, placebo-controlled RCT
(ClinicalTrials.gov NCT00814307; ORAL Solo), con-
ducted at 94 centers worldwide (February 2009 to June
2010) in compliance with the Declaration of Helsinki and
International Conference on Harmonisation Good Clinical
Practice Guidelines. The final protocol was approved by
Institutional Review Boards and/or Independent Ethics
Committees at the investigational sites (Additional file 1:
Table S1). Patients provided written, informed consent.
Details of the trial design and patient population are
reported elsewhere [21]. Eligible patients were ≥18 years
old, with RA for ≥6 months diagnosed by the American
College of Rheumatology (ACR) 1987 Revised Criteria,
with active disease (≥6 tender joints and ≥6 swollen joints;
erythrocyte sedimentation rate >28 mm/h (measured in
the local laboratory); and/or C-reactive protein >7 mg/L).
Patients were required to have prior inadequate responses
and/or intolerability to ≥1 cDMARD or bDMARD
(499 patients (82.3 %) had prior inadequate response
to methotrexate). A 4-week washout of failed DMARDs
was required (12 weeks for abatacept and toci-
lizumab). Stable doses of antimalarial drugs, non-steroidal
anti-inflammatory drugs (NSAIDs), and corticosteroids
(≤10 mg/day prednisone equivalent) were permitted.
Patients were randomized 4:4:1:1 to receive tofacitinib
5 mg BID or tofacitinib 10 mg BID, or placebo for
3 months followed by tofacitinib 5 mg BID or tofacitinib
10 mg BID. At month 3, all placebo patients were
switched blindly to active treatment and received tofaciti-
nib for the next 3 months. Randomization was performed
using an automated web/telephone system (Impala, Pfizer
Inc, USA, New York, NY). The study was patient-blinded,
investigator-blinded and sponsor-blinded.
Assessment of patient-reported outcomes
Patient Global Assessment of Disease Activity (PtGA)
and Patient Assessment of Pain (Pain) were evaluated
using the 100-mm visual analog scale (VAS). Physical
function was evaluated by the Health Assessment
Questionnaire-Disability Index (HAQ-DI); HRQoL was
evaluated by the Medical Outcomes Survey (MOS) Short
Form-36 (SF-36; Version 2, Acute) questionnaire, which
assesses eight domains (scores range from 0–100, with
higher scores indicating better HRQoL): physical func-
tioning (PF), role physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role
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and normalized domain scores are grouped into Physical
Component Summary (PCS) and Mental Component
Summary (MCS) scores. The Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F) scale was
used to assess fatigue/tiredness and the MOS Sleep
Scale, the quality of sleep.
PtGA, Pain, and HAQ-DI were assessed at all time
points (baseline, week 2, months 1, 2, 3, 4, 5, and 6,
and/or early termination). Time-to-event data were
collected using an interactive voice response system
(IVRS) daily diary from baseline through day 14 for
PtGA (IVRS) and IVRS Pain. Time-to-event data were
only collected from patients in the USA. The SF-36,
FACIT-F, and MOS Sleep Scale were assessed at baseline,
months 3 and 6, and/or early termination. Changes from
baseline were compared with published values for mini-
mum clinically important differences (MCID): ≥10 points
in VAS PtGA and Pain [27–30], ≥0.22 points in HAQ-DI
[27], ≥2.5 points, and ≥5 points in SF-36 summary and
domain scores, respectively, [31–36] and ≥4 points in
FACIT-F [37]. No MCID values have been determined for
the MOS Sleep Scale.
Disease activity
The Disease Activity Score based on C-reactive protein
and 28 tender joint count and 28 swollen joint count
(DAS28-3(CRP)) was used for comparison with results
from PROs, because DAS28-3(CRP) is not composed of
any of the PROs of interest.
Statistical analyses
This manuscript focuses on the month 3 time point be-
fore placebo patients were switched to tofacitinib; ana-
lyses at 6 months examined whether improvements at
3 months in those receiving active therapy were sus-
tained, and assessed changes following blinded switching
of placebo patients to tofacitinib at 3 months. All ana-
lyses were based on the full analysis set, including all
randomized patients who received at least one dose of
study drug (modified intention to treat) with at least one
post-baseline measurement. Furthermore, if a variable
was expressed as change from baseline then there had to
have been a non-missing baseline value.
Mean changes from baseline in continuous end points
were expressed as least squares mean (LSM), and ana-
lyzed using a mixed-effects longitudinal model, which
included effects of treatment and visit (geographic region
of the investigative site, baseline value of the dependent
variable, and the treatment-by-visit interaction), while pa-
tients were treated as a random effect.
The percentage of patients reporting improvements
MCID was compared between tofacitinib and placebo
groups using a normal approximation to the binomial(by forming a z score) to calculate numbers needed to
treat (NNT). NNT was considered to be statistically sig-
nificant if the percentage of responders by the MCID
differed statistically from placebo. Pearson correlations
of changes from baseline at month 3 in DAS28-3(CRP)
with changes from baseline in HAQ-DI, Pain, and PtGA
were calculated.
Statistical significance was declared for p ≤0.05, with
no adjustment for multiple comparisons. Formal statis-
tical comparisons between tofacitinib 5 and 10 mg BID
dose groups were not performed as the study was not
powered for these subgroup comparisons.
Results
Patients
Between February 2009 and June 2010, 611 patients were
randomized to receive tofacitinib 5 mg BID (n = 244),
tofacitinib 10 mg BID (n = 245), placebo followed by tofa-
citinib 5 mg BID (n = 61), and placebo followed by tofaci-
tinib 10 mg BID (n = 61); 610 patients received at least
one dose of study drug and 555 (91.0 %) completed the
trial [21]. Most patients were Caucasian and female, with
a mean age of 49.7–52.4 years across treatment groups
and mean disease duration of 7.7–8.6 years [21].
Baseline values for SF-36 PCS and MCS scores were
approximately 2 SD and 1 SD (10 points) below the
normative value of 50 points (based on age- and gender-
matched US normative data specific to this study popu-
lation). Baseline domain scores were lowest in PF and
RP domains (47–49 points lower than age- and gender-
matched normative data), followed by BP and GH
domains (34–36 points lower), RE, SF, MH and VT.
Age- and gender-matched US normative data specific to
this study population are plotted in Fig. 1 and baseline
domain scores are presented in Table 1 [38, 39].
Patient-reported outcomes
Patient global assessment of disease activity
At month 3, LSM changes from baseline were statisti-
cally significant with tofacitinib 5 and 10 mg BID treat-
ment versus placebo (p < 0.0001), and exceeded the
MCID (≥10 points) (Table 1; Fig. 2a). Statistically signifi-
cant changes from baseline were evident at week 2 and
months 1 and 2 for both doses of tofacitinib versus
placebo (Fig. 2a; Additional file 2: Table S2) and further
improvements occurred through month 6. Significantly
more patients receiving tofacitinib reported improve-
ments ≥ the MCID versus placebo (Fig 3a; Additional file
3: Table S3). Sequential decreases from baseline in IVRS
PtGA occurred from approximately 3 days post-baseline
(Fig. 4a), with greatest improvements observed in the
10 mg BID group from 6–15 days post-baseline. Placebo
patients who were switched to tofacitinib reported clinic-
ally meaningful changes between months 3 and 6 (Table 1).
Fig. 1 Short Form-36 (SF-36) domain scores at month 3. Spydergrams of SF-36 domain scores at month 3, with a US age- and gender-matched
normative population as a comparator. a Placebo at baseline and month 3. b Tofacitinib 5 mg twice daily (BID) at baseline and month 3. c Tofacitinib
10 mg BID at baseline and month 3. d Baseline scores for each treatment group. e Weighted combined baseline score + placebo + tofacitinib 5 mg
BID + tofacitinib 10 mg BID. a-d Treatment group baselines (using separate colors in d). e Weighted combined baseline across all treatment groups.
Placebo, n = 122 at baseline, and n = 108 at month 3; tofacitinib 5 mg BID, n = 239 at baseline and n = 235 at month 3; tofacitinib 10 mg, n = 243 at
baseline and n = 224 at month 3. Study values were normalized using means and SDs. See Ware et al. [38]. BP bodily pain, GH general health,
MH mental health, PF physical function, RE role emotional, RP role physical, SF social functioning, VT vitality
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Table 1 Baseline values and changes from baseline at months 3 and 6 for patient-reported outcome measures




BID (n = 243)
Tofacitinib 10 mg




BID (n = 243)
Tofacitinib 10 mg
BID (n = 245)
Placebo→ Tofacitinib
5 mg BID (n = 61)
Placebo→ Tofacitinib
10 mg BID (n = 61)
Tofacitinib 5 mg
BID (n = 243)
Tofacitinib 10 mg
BID (n = 245)
PtGA 62.63 (21.91) 61.66 (22.00) 63.46 (23.23) −11.19 (2.10) −26.99 (1.45)*** −30.94 (1.47)*** −28.07 (2.97) −29.62 (3.05) −30.25 (1.47) −33.99 (1.50)
Pain 61.79 (21.27) 61.35 (22.27) 62.03 (23.63) −10.71 (2.14) −26.94 (1.47)*** −31.06 (1.50)*** −26.01 (3.02) −29.48 (3.10) −29.19 (1.49) −34.11 (1.52)
HAQ-DI† 1.53 (0.65) 1.53 (0.66) 1.50 (0.64) −0.19 (0.05) −0.50 (0.03)*** −0.57 (0.03)*** −0.43 (0.07) −0.59 (0.07) −0.62 (0.03) −0.67 (0.04)
SF-36 component
summary scores
SF-36 PCS score 32.21 (8.35) 31.23 (8.03) 31.37 (7.39) 2.63 (0.78) 6.79 (0.53)*** 8.55 (0.55)*** 5.18 (1.09) 6.14 (1.11) 8.01 (0.53) 9.66 (0.55)
SF-36 MCS score 39.87 (11.62) 41.36 (11.68) 42.19 (12.44) 1.09 (0.89) 4.11 (0.61)* 5.39 (0.62)*** 3.83 (1.23) 8.01 (1.26) 4.62 (0.60) 4.80 (0.62)
SF-36 domain scores
Physical functioning 31.41 (9.66) 30.09 (9.31) 30.51 (8.76) 2.17 (0.88) 6.15 (0.60)** 6.97 (0.62)*** 4.02 (1.22) 5.15 (1.26) 6.95 (0.60) 8.17 (0.62)
Role physical 33.33 (8.97) 32.84 (8.87) 33.45 (8.69) 1.88 (0.83) 5.89 (0.57)*** 7.53 (0.58)*** 4.33 (1.16) 6.31 (1.20) 7.01 (0.57) 7.85 (0.59)
Bodily pain 32.77 (7.67) 32.41 (7.57) 32.74 (7.55) 3.91 (0.86) 8.26 (0.58)*** 10.84 (0.60)*** 7.88 (1.21) 10.28 (1.25) 9.44 (0.59) 11.30 (0.61)
General health 34.70 (9.00) 34.86 (8.72) 35.71 (8.86) 2.44 (0.75) 4.76 (0.51)* 6.34 (0.53)*** 5.26 (1.06) 5.37 (1.10) 6.51 (0.52) 7.49 (0.54)
Vitality 40.13 (9.82) 41.22 (10.06) 41.04 (10.27) 2.03 (0.81) 6.56 (0.55)*** 8.49 (0.57)*** 4.67 (1.15) 8.27 (1.18) 6.87 (0.56) 8.30 (0.58)
Social functioning 35.16 (10.34) 36.78 (11.04) 36.07 (11.27) 0.62 (0.91) 5.29 (0.62)*** 7.51 (0.64)*** 3.54 (1.29) 8.21 (1.34) 6.05 (0.63) 6.83 (0.65)
Role emotional 35.17 (13.11) 34.26 (12.63) 36.70 (13.03) 1.20 (1.05) 4.07 (0.72)* 5.50 (0.74)** 4.54 (1.43) 6.96 (1.47) 5.95 (0.70) 5.56 (0.72)
Mental health 38.43 (12.36) 40.05 (11.49) 40.50 (12.57) 2.19 (0.88) 4.71 (0.60)* 5.52 (0.62)* 4.09 (1.23) 8.02 (1.27) 4.52 (0.60) 5.35 (0.62)
FACIT-F 27.17 (10.88) 27.90 (10.70) 27.72 (11.15) 2.84 (0.82) 6.70 (0.56)*** 8.01 (0.58)*** 6.57 (1.16) 9.11 (1.20) 6.98 (0.57) 8.63 (0.58)
MOS Sleep Scale 47.32 (21.24) 42.45 (18.38) 43.09 (20.41) −4.81 (1.48) −7.13 (1.02) −10.18 (1.04)* −8.43 (2.06) −10.50 (2.14) −7.48 (1.02) −9.98 (1.05)
†Co-primary endpoint at month 3. *p < 0.05; **p < 0.001; *** p < 0.0001 vs placebo. BID twice daily, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-
Disability Index, LSM least squares mean, MCS Mental Component Summary, MOS Medical Outcomes Study, Pain Patient Global Assessment of Pain, PCS Physical Component Summary, PtGA Patient Global Assessment













Fig. 2 Least squares mean (LSM) changes from baseline: Patient Global Assessment of Disease Activity (PtGA) (a), Patient Global Assessment of
Pain (Pain) (b), and Health Assessment Questionnaire-Disability Index (HAQ-DI) (c), over time; *p <0.05; **p <0.01; ***p <0.0001 vs placebo. MCID
minimum clinically important difference, BID twice daily, SE standard error
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improvements ≥ the MCID at month 3 were numeric-
ally greater for 10 mg BID compared with 5 mg BID,
with a lower NNT (3.8 vs 4.0) (Fig. 3a; Additional file
3: Table S3). NNT over time for PtGA compared with
ACR20/50/70 and DAS28-3(CRP) are shown in
Additional file 4: Figure S1. Correlation at month 3
with DAS28-3(CRP) (both expressed as LSM changes
from baseline) ranged from 0.32 (tofacitinib 10 mg BID)
to 0.51 (placebo); all were statistically significant.
Pain
At month 3, LSM changes from baseline were statisti-
cally significant in patients receiving tofacitinib 5 and
10 mg BID versus placebo (p < 0.0001), and exceeded
the MCID (Table 1; Fig. 2b). Statistically significant
changes from baseline were also reported at week 2 and
months 1 and 2 for both doses of tofacitinib versus pla-
cebo (Fig. 2b; Additional file 2: Table S2) and further im-
provement occurred through month 6 in both active
treatment groups (Table 1). Significantly more patients re-
ceiving tofacitinib reported improvements ≥ the MCID
versus placebo (Fig. 3b; Additional file 3: Table S3). Pa-
tients reported sequential decreases in IVRS Pain from ap-
proximately 3 days post-baseline (Fig. 4b); more patientsin the 10 mg BID group reported sustained improvements
from 4–13 days post-baseline but formal statistical ana-
lyses between 5 mg BID and 10 mg BID were not per-
formed. Placebo patients who were switched to tofacitinib
reported clinically meaningful changes between months 3
and 6 (Table 1). Improvements in LSM values and the per-
centage of patients reporting improvements ≥ the MCID
at month 3 were numerically greater in the 10 mg BID
group compared with 5 mg BID group, with a lower NNT
(3.5 vs 4.6) (Table 1; Fig. 3b; Additional file 3: Table S3).
The NNT over time for pain compared with ACR20/50/
70 and DAS28-3(CRP) are shown in Additional file 4:
Figure S1. Correlations with DAS28-3(CRP) at month 3
(both expressed as LSM changes from baseline) ranged
from 0.32 (tofacitinib 10 mg BID) to 0.46 (placebo); all
were statistically significant.
Health assessment questionnaire-disability index
At month 3, LSM changes from baseline were statisti-
cally significant for tofacitinib 5 and 10 mg BID versus
placebo (p < 0.0001), and exceeded the MCID (≥0.22
points) (Table 1; Fig. 2c). Statistically significant changes
from baseline were also reported at week 2 (first post-
baseline assessment) and months 1 and 2 for tofacitinib
5 and 10 mg BID versus placebo (Fig. 2c; Additional file 2:
Fig. 3 (See legend on next page.)
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Fig. 3 Percentage of patients with improvements ≥ the minimal clinically important difference (MCID) at month 3. Patient Global Assessment of
Disease Activity (PtGA) (a), Patient Global Assessment of Pain (Pain) (b), Health Assessment Questionnaire-Disability Index (HAQ-DI) (c), Short Form-36
Physical Component Summary (SF-36 PCS) score (d), SF-36 Mental Component Summary (MCS) score (e), Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) (f) and SF-36 domain scores (g); *p <0.05; **p <0.01; ***p <0.0001 vs placebo. MCID ≥10 points in PtGA and Pain, ≥0.22 points
in HAQ-DI, ≥2.5 points and ≥5 points in SF-36 summary and domain scores, respectively and ≥4 points in FACIT-F. BID twice daily, BP bodily pain, GH
general health, MH mental health, NNT number needed to treat, PF physical function, RE role emotional, RP role physical, SE standard error, SF social
functioning, VT vitality
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month 6 (Table 1). Significantly more patients treated
with tofacitinib reported improvements ≥ the MCID
compared with placebo (Fig. 3c; Additional file 3: Table S3).
Placebo patients advanced to tofacitinib reported clinic-
ally meaningful changes between month 3 and month 6
(Table 1). Improvements in LSM values and the per-
centage of patients reporting improvements ≥ the MCID
at month 3 were numerically greater in the 10 mg BID
compared with the 5 mg BID group, with a lower NNT
(4.0 vs 5.7) (Table 1; Fig. 3c; Additional file 3: Table S3).
The NNT over time for HAQ-DI compared with ACR20/
50/70 and DAS28-3(CRP) are shown in Additional file 4:Fig. 4 Time to first sequential decrease from baseline. Interactive voice respo
and IVRS Patient Global Assessment of Pain (Pain) (b). A sequential decrease w
measure. BID twice dailyFigure S1. Numerically more patients reported values
consistent with normative scores in HAQ-DI (≤0.5) with
tofacitinib 5 and 10 mg BID versus placebo (Additional
file 5: Table S4). Correlations with DAS28-3(CRP) at
month 3 ranged from 0.37 with tofacitinib 5 mg BID to
0.47 with placebo; all were statistically significant.
Health-related quality of life assessed by Short Form-36
LSM changes from baseline in SF-36 PCS and MCS scores
were statistically significant for 5 mg BID (p < 0.0001 and
p < 0.05, respectively) and 10 mg BID (both p < 0.0001)
compared with placebo at month 3 (first post-baseline as-
sessment), and exceeded the MCID (≥2.5 points) (Table 1).nse system (IVRS) Patient Global Assessment of Disease Activity (PtGA) (a)
as defined as at least 2 days of consecutive improvement in each
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groups reported improvements ≥ the MCID in PCS scores
versus placebo (Fig. 3d); the percentage of patients report-
ing improvements ≥ the MCID in MCS scores were not
statistically significant for the tofacitinib treatment groups
versus placebo (Fig. 3e). LSM changes from baseline and
the percentage of patients reporting improvements ≥ the
MCID at month 3 were numerically greater for 10 mg
BID compared with 5 mg BID, with a lower NNT (PCS:
3.2 vs 4.2; MCS: 12.0 vs 13.6) (Table 1; Fig. 3d, e).
Changes from baseline in SF-36 domain scores
compared with age and gender US normative data are
presented in Fig. 1. At month 3, patients receiving
tofacitinib reported statistically significant (p < 0.05 to
p < 0.0001) and clinically meaningful improvements
(≥5 points) from baseline in all domain scores (Table 1).
Compared with placebo, significantly more patients re-
ceiving tofacitinib reported improvements ≥ the MCID
(≥5 points) in the PF, RP, BP GH, VT, and SF domains
(Fig. 3g). The percentage of patients reporting improve-
ments meeting or exceeding US normative SF-36 scores
for both tofacitinib doses compared with placebo are pre-
sented in Additional file 6: Figure S2.
Functional assessment of chronic illness therapy-fatigue
Statistically significant improvements from baseline were
observed in the tofacitinib groups for FACIT-F (p < 0.0001)
at month 3 (first post-baseline assessment) (Table 1).
Significantly more patients receiving tofacitinib re-
ported improvements ≥ the MCID (≥4 points) versus
placebo (Fig. 3f). Further improvements occurred through
month 6 in the active treatment groups (Table 1). Placebo
patients who switched to tofacitinib reported clinically
meaningful changes between months 3 and 6 (Table 1).
LSM values and the percentage of patients reporting im-
provements ≥ the MCID at month 3 were numerically
greater in the 10 mg BID group compared with the 5 mg
BID group, with a lower NNT (5.0 vs 6.1) (Table 1;
Fig. 3f).
Medical outcomes study sleep scale
Statistically significant changes from baseline in the
MOS Sleep Scale were evident at month 3 (first post-
baseline assessment) for tofacitinib 10 mg BID (p < 0.05)
but not for tofacitinib 5 mg BID (p = 0.1926) versus pla-
cebo (Table 1). Further improvements occurred through
month 6 in patients receiving active treatment, and simi-
lar changes from months 3–6 were reported by placebo
patients who switched to tofacitinib (Table 1).
Discussion
It has been demonstrated that PROs provide quantitative
data of comparable value to more traditional measures
(e.g., joint counts and laboratory tests), discriminatetreatment effects, are easy to perform, and are important
for long-term health outcomes [40]. Furthermore, HRQoL
measures are unique in that they measure the impact of
the underlying disease, treatment-related benefits and
adverse effects, and offer the opportunity for comparison
to other disease populations. PROs, clinical assessments
and imaging of joints are all important in assessing RA
patients and their responses to treatment, and should be
utilized together to provide a holistic view of disease activ-
ity and wellbeing.
In this phase 3 trial, DMARD-IR patients receiving
tofacitinib 5 and 10 mg BID monotherapy reported
statistically significant and clinically meaningful improve-
ments in PtGA, Pain, HAQ-DI, HRQoL, and fatigue at
3 months, with significant changes versus placebo ob-
served at the first time point measured post-baseline, as
early as 2 weeks. This is particularly important as patients
were expected to have active disease at the time they initi-
ated protocol treatment. In those patients continuing tofa-
citinib therapy, further improvements in LSM values were
reported at month 6, and improvements in LSM values
were greater for 10 versus 5 mg BID. Placebo patients
who switched to tofacitinib at month 3 reported im-
provements through month 6, confirming the results of
the primary analysis at 3 months. Benefits of treatment
with tofacitinib, as demonstrated by these PROs, were
consistent with primary efficacy data, which showed statis-
tically significant improvements in ACR responses, and
changes from baseline in HAQ-DI with tofacitinib 5 and
10 mg BID monotherapy versus placebo [21].
Improvements in PtGA, Pain, and HAQ-DI with tofa-
citinib versus placebo were similar, and consistent with
changes reported for fatigue and HRQoL. Across all five
of these PROs – PtGA, Pain, HAQ-DI, SF-36 PCS, and
FACIT-F – the proportion of patients reporting im-
provements ≥ the MCID ranged from 61–73 % for 5 mg
BID and 65–77 % for 10 mg BID. Improvements in LSM
changes from baseline to months 3 and 6, and from 3 to
6 months in placebo patients switched to tofacitinib,
were consistently greater for 10 mg BID versus 5 mg
BID. Across these five PROs, the NNT values for treat-
ment with 10 mg BID ranged from 3.2–5.0 compared with
4.0–6.1 for 5 mg BID, with such low numbers reflecting
the value of therapy to patients.
In active RA, physical functioning, pain and fatigue
have been shown to be important outcomes from the
patient’s perspective [41] Tofacitinib therapy resulted in
improvements in each of these aspects of the disease,
measured by PtGA, Pain, HAQ-DI, FACIT-F, and the
MOS Sleep Scale. Benefits of tofacitinib treatment were
rapid in onset and significant improvements were
reported at week 2 for PtGA, Pain, and HAQ-DI, and
differentiation from baseline was seen as early as 3 days
after treatment initiation for IVRS PtGA and IVRS Pain.
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HRQoL at baseline, measured by SF-36, versus age- and
gender-matched US normative data as a benchmark com-
parison (Fig. 1). This was particularly evident in the PF,
RP, BP, GH, SF, and RE domains, consistent with the broad
impact of active RA on physical, social, emotional, and
mental functioning. Following tofacitinib treatment, pa-
tients reported statistically significant and clinically mean-
ingful improvements in both summary scores and all
domains of the SF-36 with both tofacitinib doses.
Statistically significant and clinically meaningful im-
provements in the VT domain resulted in scores that
approached (5 mg BID) and met (10 mg BID) normative
values from the US general population at month 3. These
are reflected by improvements in the FACIT-F scores,
which were statistically significantly greater versus placebo,
and exceeded the MCID. Not only were changes from
baseline greatest in those domains with the lowest scores
at baseline (PF, RP, and BP), but improvements were also
evident in other domains, including RE and MH, which
correlate strongly with the classic instruments used to
diagnose clinical depression. RA is known to have a major
negative psychological impact, with depression occurring
in 13–20 % of patients [42] or more [43] based on clinical
assessments. Thus, it appears that tofacitinib not only
improves physical functioning, pain and fatigue, but also
social and emotional functioning and wellbeing.
Patients receiving placebo monotherapy improved at
3 months, although mean improvements were small in
magnitude: below the MCID in the HAQ-DI and FACIT-F,
and meeting the MCID in the PtGA, Pain, and PCS scores.
Fewer than 50 % of placebo patients reported changes the
MCID (43–48 %) in all PRO endpoints compared with
≥61 % and ≥68 % in the 5 and 10 mg BID groups,
respectively.
Conclusions
This phase 3 randomized clinical trial, ORAL Solo, demon-
strates that treatment with tofacitinib monotherapy for
3 months provides relief from the broad burden of active
RA, favorably impacting a wide range of PROs. These
include self-assessment of physical function, pain, disease
activity, and HRQoL, with low NNT and early onset of
improvement in patients with a prior inadequate response
to cDMARDs and/or bDMARDs.
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